ClinicalTrials.gg
RecruitingNCT06300697Updated Nov 10, 2026

Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

An interventional study of Data and biospecimen collection and Skin biopsies in Atopic Dermatitis, Food Allergy and Healthy, sponsored by University of Michigan. Recruiting at 1 site in United States. Open to participants aged 10 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Michigan · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
10 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
171st of 544
200 · median 96
Started
2024
with 33 others
No phase
68 of 639
4 open now
Primary completion
2028-03
later than 78 of 115 live
Registered
544th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 171st largest by planned enrollment of the 544 interventional ones that give a count, is one of 34 that started in 2024, is one of 68 with no phase, reaches primary completion later than 78 of the 115 other live ones, and was the 544th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 10 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future.

This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various times during the oral food challenge. This study will create a molecular map of the pathology of atopic dermatitis and food allergy. This information will be deployed to evaluate the hypothesis that atopic dermatitis and food allergy share unique genetic transcriptional signals in which the study team can then further analyze pathological pathways and cell types.

Read the detailed description

This study will be funded by the National Institute of Health. Once the funds are received, the registration will be updated with this information.

03

Conditions studied

  • Atopic Dermatitis
  • Food Allergy
  • Healthy

Keywords

  • Blood Samples
  • Skin Samples
  • Transepidermal water loss (TEWL) monitor
  • Allergic reaction
04

Who can participate

Ages eligible
10 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Food allergy-only group Inclusion Criteria:

  • Have a known history of food anaphylaxis to peanut, tree nut, egg, milk, or sesame confirmed by an allergist.
  • Have had skin and blood food allergy testing to the food allergen in question within the past 6 months. Meet the 80% likelihood positive predictive value threshold for allergy based on at least 1 of either the skin or blood immunoglobulin E (IgE) tests per current literature corrected for age. See protocol for more details.
  • No history of atopic dermatitis

Food allergy plus atopic dermatitis group Inclusion Criteria:

- Meet the "food allergy only group" inclusion criteria except this group must also have atopic dermatitis.

Atopic dermatitis without food allergy Inclusion Criteria:

  • Have a present diagnosis of atopic dermatitis by an allergist and/or dermatologist.
  • Have no history of food allergy, past or present.

Control Group Inclusion Criteria:

- No history of food allergy or atopic dermatitis, past or present.

Exclusion Criteria for all groups:

  • People younger than age 10 or older than age 55
  • Any active cardiovascular disease, cancer, pulmonary disease except well-controlled asthma, or other condition that would preclude an OFC otherwise. Mild conditions that would not preclude an OFC are allowed (i.e., controlled hypertension or a surgically removed skin cancer that is resolved would not be exclusionary for this study, for example).
  • Any medication use that cannot be stopped temporarily for the OFC that would interfere with the OFC result. Medications in this category include antihistamines (first or second generation) within 1 week.
  • Any skin condition aside from atopic dermatitis per inclusion criteria groups that might impact the study, including such conditions as skin conditions (such as psoriasis), congenital ichthyoses, hyper-IgE syndromes.
  • Any recent change (within 6 months) of starting or stopping a biologic medication, such as dupilumab, tezepelumab, or others that might interfere with atopic dermatitis or food allergy.
  • Any past or present history of oral immunotherapy (OIT) for any food allergen.
  • Pregnancy - females of childbearing age will be asked and self-report pregnancy status.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Control group Adult

    Participation will be approximately 14 days after enrollment.

    Other: Data and biospecimen collection · Other: Skin biopsies · Other: Oral Food Challenge (OFC) procedures

  • Other
    Food allergy-only group

    Participation will be approximately 14 days after enrollment.

    Other: Data and biospecimen collection · Other: Skin biopsies · Other: Oral Food Challenge (OFC) procedures

  • Other
    Food allergy plus atopic dermatitis group

    Participation will be approximately 14 days after enrollment.

    Other: Data and biospecimen collection · Other: Skin biopsies · Other: Oral Food Challenge (OFC) procedures

  • Other
    Atopic dermatitis without food allergy group

    Participation will be approximately 14 days after enrollment.

    Other: Data and biospecimen collection · Other: Skin biopsies · Other: Oral Food Challenge (OFC) procedures

  • Other
    Control Group less than 18 years old

    Participation will be approximately 14 days after enrollment.

    Other: Data and biospecimen collection · Other: Oral Food Challenge (OFC) procedures

Interventions

  • OtherData and biospecimen collection

    Enrolled participants will have health-related information and blood specimens collected.

  • OtherSkin biopsies

    Participants will be asked to provide one or two skin biopsies (days 1 and 2) from the forearm, unless the participant is a healthy child (no food allergy and no atopic dermatitis), in which case there will be no skin biopsy.

  • OtherOral Food Challenge (OFC) procedures

    Participants will have the choice of consenting to an OFC (approximately 2-4 hours) to peanut, tree nut, egg, milk, or sesame. If there is no allergy history, the study team will conduct an oral food challenge to one of the choices. The OFC will occur in the clinical research area. and done the same as a clinical care OFC. A transepidermal water loss monitor will be applied to participant's arm with a sticky pad and will stay on the arm for the challenge. Food doses will be given in small amounts that increase in size up to a defined single serving of the food based upon the participants age/size. The OFC will proceed until a full dose is consumed without symptoms, or until anaphylaxis occurs. Depending upon the participant's reaction to the oral food challenge, the participant may be requested to return the next day for a research visit that would take less than an hour. The 24-hour post oral food challenge visit will include an interview to assess condition and a blood sample.

06

What researchers measure

Primary outcomes

  1. Anaphylaxis occurrence rates in each group

    Anaphylaxis likelihood will be defined by the Brighton criteria. Any Brighton Level 1, 2, or 3 anaphylaxis. Score 1 = definite anaphylaxis, score 2 = probable anaphylaxis, score 3 = possible anaphylaxis.

    Time frame: Approximately 4 hours (Day 1 during the food challenge)

Secondary outcomes

  1. Anaphylaxis severity in each group

    This will be graded on a scale of 1 to 5 (where 1 = mild, 5 = death) according to criteria set forth in the Consortium for Food Allergy Research (CoFAR) Grading Scale.

    Time frame: Approximately 4 hours (Day 1 during the food challenge)

  2. Reaction rates in each group

    Any objective symptom of allergic reaction occurs (e.g., hives, angioedema, vomiting, wheeze, etc.) not rising to the definition of anaphylaxis.

    Time frame: Approximately 4 hours (Day 1 during the food challenge)

  3. Anaphylaxis likelihood in each group based on the Brighton score

    The Brighton score gives a 0-3 score of anaphylaxis likelihood (0 = no anaphylaxis, 3 = highly likely).

    Time frame: Approximately 4 hours (Day 1 during the food challenge)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2028, 49 months after the start.

Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 49 months is above that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Mar 2027 → Mar 2028 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 8, 2024
StartActual
Feb 15, 2024
Primary completionEst.
Mar 2028was Mar 2027
CompletionEst.
Mar 2028was Mar 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 2027→Mar 2028
Nov 10, 2026
Study completion
Mar 2027→Mar 2028
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Mar 2027→Mar 2028
    Study completion Mar 2027→Mar 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06300697
Responsible party
Charles (Chase) Schuler (Assistant Professor of Internal Medicine and Assistant Professor of Mary H Weiser Food Allergy, University of Michigan) — Principal investigator
First posted
Mar 8, 2024
Start date
Feb 15, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Bridgette Kaul
Contact
foodallergyclinicalresearch@med.umich.edu
734-647-8284
Chase Schuler, MD
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion